Syncom Formulations (India) Ltd (SYNCOMF) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 831770,
    "name": "Syncom Formul.",
    "stock_name": "Syncom Formul.",
    "full_name": "Syncom Formulations (India) Ltd",
    "name_url": "stocks-analysis/syncom-formul",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "13.36",
    "chg": 0.36,
    "chgp": "2.77%",
    "dir": 1,
    "prev_price": "13.00",
    "mcapval": "1,252.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 524470,
    "symbol": "SYNCOMF",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE312C01025",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "25.15 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/syncom-formul-831770-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Syncom Formul. Sees Revision in Market Evaluation Amidst Challenging Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/syncom-formul-downgraded-to-sell-by-marketsmojo-amid-weak-financial-and-technical-signals-3737096",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SyncomFormul_mojoScore_3737096.png",
        "date": "2025-11-30 10:24:43",
        "description": "Syncom Formul., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in its fundamental and technical outlook. This adjustment comes amid subdued financial performance and a bearish technical stance, signalling a cautious market perspective on the stock’s near-term prospects."
      },
      {
        "title": "Why is Syncom Formul. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-syncom-formul-fallingrising-3726933",
        "imagepath": "",
        "date": "2025-11-25 01:16:57",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>On 24-Nov, Syncom Formulations’ stock price closed lower by ₹0.36, marking a 2.27% decrease. This decline is part of a broader pattern, with the stock having lost 6.57% over the past week, significantly underperforming the Sensex benchmark, which remained almost flat with a marginal 0.06% change during the same period. Over the last month, the stock also fell by 6.96%, while the Sensex gained 0.82%. Year-to-date, the stock has declined sharply by 22.50%, contrasting with the Sensex’s robust 8.65% gain. This underperformance extends to the one-year horizon, where Syncom Formulations’ shares have dropped 20.55%, whereas the Sensex rose by 7.31%.</p>\n<p>Further compounding the negative sentiment, the stock has been trading below all k..."
      },
      {
        "title": "Is Syncom Formul. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-syncom-formul-overvalued-or-undervalued-3713610",
        "imagepath": "",
        "date": "2025-11-19 08:09:23",
        "description": "As of 18 November 2025, the valuation grade for Syncom Formul. has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 24.53, an EV to EBITDA ratio of 21.00, and a PEG ratio of 0.27. These ratios suggest that while the company is priced reasonably compared to its earnings growth potential, it is not undervalued.\n\nIn comparison to its peers, Syncom Formul. stands out against Sun Pharma, which is considered expensive with a PE ratio of 36.56, and Cipla, which is attractive with a PE ratio of 22.49. The fair valuation of Syncom Formul. indicates that it is positioned well within the industry, especially when compared to the higher valuations of some competitors. Notably, while the stock has underperformed the Sensex year-to-date, it has shown significant returns over longer periods, reflecting its potential for growth...."
      },
      {
        "title": "Is Syncom Formul. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-syncom-formul-overvalued-or-undervalued-3706071",
        "imagepath": "",
        "date": "2025-11-17 08:10:23",
        "description": "As of 14 November 2025, the valuation grade for Syncom Formul. has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 24.77, an EV to EBITDA of 21.23, and a PEG ratio of 0.28, indicating that while the company has a relatively low growth expectation, its valuation remains high compared to its earnings.\n\nIn comparison to peers, Syncom Formul.'s PE ratio is significantly lower than Sun Pharma. Inds., which stands at 36.49, and Divi's Lab., which is at 69.65, both categorized as expensive to very expensive. Conversely, Cipla, which is rated attractive, has a PE ratio of 22.72, suggesting that Syncom Formul. may not be as competitively priced within its sector. The stock has underperformed the Sensex over the past year, with a return of -20.15% compared to the Sensex's 9.00%, reinforcing the notion that it is cu..."
      },
      {
        "title": "Is Syncom Formul. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-syncom-formul-overvalued-or-undervalued-3705432",
        "imagepath": "",
        "date": "2025-11-16 08:09:59",
        "description": "As of 14 November 2025, the valuation grade for Syncom Formul. has moved from very expensive to expensive. The company is currently considered overvalued based on its financial ratios. The PE ratio stands at 24.77, while the EV to EBITDA ratio is 21.23, and the PEG ratio is notably low at 0.28, indicating that the stock may not be justified at its current price given its growth prospects.\n\nIn comparison to its peers, Syncom Formul. has a higher PE ratio than Cipla, which is attractive at 22.72, and significantly higher than Dr. Reddy's Labs, which has a PE of 18. Additionally, the company's EV to EBITDA ratio is also above the industry average, further supporting the overvaluation stance. While the stock has performed well over the long term, with a 5-year return of 802.17%, recent performance has lagged behind the Sensex, with a year-to-date decline of 17.00% compared to the Sensex's gain of 8.22%...."
      },
      {
        "title": "Is Syncom Formul. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-syncom-formul-overvalued-or-undervalued-3704637",
        "imagepath": "",
        "date": "2025-11-15 08:10:04",
        "description": "As of 14 November 2025, the valuation grade for Syncom Formul. has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 24.77, an EV to EBITDA of 21.23, and a PEG ratio of 0.28, which indicates potential growth relative to its price. \n\nIn comparison to peers, Syncom Formul.'s PE ratio is significantly lower than Sun Pharma's 36.49 and Divi's Lab's 69.65, both categorized as expensive and very expensive, respectively. However, it is higher than Cipla's attractive PE of 22.72, suggesting that while Syncom Formul. is overvalued, it remains competitive within the industry. The recent stock performance shows a 3.30% return over the past week, outperforming the Sensex's 1.62%, but the year-to-date return of -17.00% highlights ongoing challenges...."
      },
      {
        "title": "Syncom Formulations Reports Strong Financial Growth Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/syncom-formulations-financial-trend-improves-from-positive-to-very-positive-with-strong-growth-metrics-3701267",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SyncomFormulati_fintrenddot_3701267.png",
        "date": "2025-11-14 11:02:29",
        "description": "Syncom Formulations (India) has reported impressive financial results for the quarter ending September 2025, with a 72.46% increase in Profit After Tax and a 25.87% rise in net sales. The company achieved its highest Return on Capital Employed and demonstrated strong operational efficiency, despite facing recent market challenges."
      },
      {
        "title": "Is Syncom Formul. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-syncom-formul-overvalued-or-undervalued-3700191",
        "imagepath": "",
        "date": "2025-11-14 08:11:13",
        "description": "As of 13 November 2025, the valuation grade for Syncom Formulations has moved from expensive to very expensive. This indicates a significant shift in the perception of the company's valuation, suggesting that it is currently overvalued. The key ratios reflect this assessment, with a PE Ratio of 25.08, an EV to EBITDA of 22.41, and a Price to Book Value of 4.62, all of which are elevated compared to industry norms.\n\nIn comparison to its peers, Syncom Formulations' valuation metrics stand out unfavorably. For instance, Sun Pharma has a PE Ratio of 36.15, while Divi's Lab shows an even higher valuation at 70.4. In contrast, Cipla, which is rated as attractive, has a much lower PE Ratio of 22.65, indicating that Syncom Formulations is not only overvalued but also less competitive in terms of valuation relative to its peers. Additionally, while Syncom has shown strong returns over the long term, its recent perfo..."
      },
      {
        "title": "How has been the historical performance of Syncom Formul.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-syncom-formul-3695434",
        "imagepath": "",
        "date": "2025-11-13 00:24:52",
        "description": "Answer:\nThe historical performance of Syncom Formul. shows significant fluctuations in key financial metrics over the years.\n\nBreakdown:\nSyncom Formul. reported net sales of 465.01 Cr for the year ending March 2025, a substantial increase from 263.39 Cr in March 2024 and 224.25 Cr in March 2023. However, this is a stark contrast to the exceptionally high net sales of 21,966.32 Cr recorded in March 2022. The company's total operating income mirrored this trend, reaching 465.01 Cr in March 2025, up from 263.39 Cr in the previous year. The total expenditure, excluding depreciation, was 410.88 Cr in March 2025, which also increased from 233.74 Cr in March 2024. Operating profit (PBDIT) for March 2025 was 71.56 Cr, showing a rise from 43.18 Cr in March 2024, while profit before tax was reported at 65.51 Cr, up from 33.95 Cr. The profit after tax for March 2025 was 49.43 Cr, compared to 25.31 Cr in March 2024. Th..."
      }
    ],
    "total": 230,
    "sid": "831770",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/syncom-formulations-india-831770"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "08-Jan-2026",
      "details": "Certificate for compliance of regulation 74(5) of the SEBI (Depositories and Participants) Regulation 2018 for the quarter ended 31st December 2025",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "08-Jan-2026",
      "details": "Certificate for compliance of regulation 74(5) of the SEBI (Depositories and participants) regulation 2018 for the quarter ended 31st December 2025.",
      "source": "BSE"
    },
    {
      "caption": "Pursuant To Regulation 30 Read With Schedule III Part A Of SEBI (LODR) Regulations 2015",
      "datetime": "03-Jan-2026",
      "details": "Pursuant to Regulation 30 read with Schedule lll Part A of SEBI (LODR) Regulations 2015 for the demand raised under section 74(5) of CGST Act 2017 for Ineligible Input Tax Credits also section 122 of CGST Act 2017 for penalty.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Syncom Formulations (India) Ltd has declared <strong>3%</strong> dividend, ex-date: 09 Sep 22",
          "dt": "2022-09-09",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Syncom Formulations (India) Ltd has announced <strong>1:10</strong> stock split, ex-date: 19 Aug 13",
          "dt": "2013-08-19",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Syncom Formulations (India) Ltd has announced <strong>5:2</strong> bonus issue, ex-date: 19 Aug 13",
          "dt": "2013-08-19",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Syncom Formulations (India) Ltd has announced <strong>1:2</strong> rights issue, ex-date: 13 May 09",
          "dt": "2009-05-13",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Syncom Formul. Sees Revision in Market Evaluation Amidst Challenging Financial Trends

2025-11-30 10:24:43

Syncom Formul., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in its fundamental and technical outlook. This adjustment comes amid subdued financial performance and a bearish technical stance, signalling a cautious market perspective on the stock’s near-term prospects.

Why is Syncom Formul. falling/rising?

2025-11-25 01:16:57

Recent Price Movement and Market Performance On 24-Nov, Syncom Formulations’ stock price closed lower by ₹0.36, marking a 2.27% decrease. This decline is part of a broader pattern, with the stock having lost 6.57% over the past week, significantly underperforming the Sensex benchmark, which remained almost flat with a marginal 0.06% change during the same period. Over the last month, the stock also fell by 6.96%, while the Sensex gained 0.82%. Year-to-date, the stock has declined sharply by 22.50%, contrasting with the Sensex’s robust 8.65% gain. This underperformance extends to the one-year horizon, where Syncom Formulations’ shares have dropped 20.55%, whereas the Sensex rose by 7.31%. Further compounding the negative sentiment, the stock has been trading below all k...

Is Syncom Formul. overvalued or undervalued?

2025-11-19 08:09:23

As of 18 November 2025, the valuation grade for Syncom Formul. has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 24.53, an EV to EBITDA ratio of 21.00, and a PEG ratio of 0.27. These ratios suggest that while the company is priced reasonably compared to its earnings growth potential, it is not undervalued. In comparison to its peers, Syncom Formul. stands out against Sun Pharma, which is considered expensive with a PE ratio of 36.56, and Cipla, which is attractive with a PE ratio of 22.49. The fair valuation of Syncom Formul. indicates that it is positioned well within the industry, especially when compared to the higher valuations of some competitors. Notably, while the stock has underperformed the Sensex year-to-date, it has shown significant returns over longer periods, reflecting its potential for growth....

Is Syncom Formul. overvalued or undervalued?

2025-11-17 08:10:23

As of 14 November 2025, the valuation grade for Syncom Formul. has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 24.77, an EV to EBITDA of 21.23, and a PEG ratio of 0.28, indicating that while the company has a relatively low growth expectation, its valuation remains high compared to its earnings. In comparison to peers, Syncom Formul.'s PE ratio is significantly lower than Sun Pharma. Inds., which stands at 36.49, and Divi's Lab., which is at 69.65, both categorized as expensive to very expensive. Conversely, Cipla, which is rated attractive, has a PE ratio of 22.72, suggesting that Syncom Formul. may not be as competitively priced within its sector. The stock has underperformed the Sensex over the past year, with a return of -20.15% compared to the Sensex's 9.00%, reinforcing the notion that it is cu...

Is Syncom Formul. overvalued or undervalued?

2025-11-16 08:09:59

As of 14 November 2025, the valuation grade for Syncom Formul. has moved from very expensive to expensive. The company is currently considered overvalued based on its financial ratios. The PE ratio stands at 24.77, while the EV to EBITDA ratio is 21.23, and the PEG ratio is notably low at 0.28, indicating that the stock may not be justified at its current price given its growth prospects. In comparison to its peers, Syncom Formul. has a higher PE ratio than Cipla, which is attractive at 22.72, and significantly higher than Dr. Reddy's Labs, which has a PE of 18. Additionally, the company's EV to EBITDA ratio is also above the industry average, further supporting the overvaluation stance. While the stock has performed well over the long term, with a 5-year return of 802.17%, recent performance has lagged behind the Sensex, with a year-to-date decline of 17.00% compared to the Sensex's gain of 8.22%....

Is Syncom Formul. overvalued or undervalued?

2025-11-15 08:10:04

As of 14 November 2025, the valuation grade for Syncom Formul. has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 24.77, an EV to EBITDA of 21.23, and a PEG ratio of 0.28, which indicates potential growth relative to its price. In comparison to peers, Syncom Formul.'s PE ratio is significantly lower than Sun Pharma's 36.49 and Divi's Lab's 69.65, both categorized as expensive and very expensive, respectively. However, it is higher than Cipla's attractive PE of 22.72, suggesting that while Syncom Formul. is overvalued, it remains competitive within the industry. The recent stock performance shows a 3.30% return over the past week, outperforming the Sensex's 1.62%, but the year-to-date return of -17.00% highlights ongoing challenges....

Syncom Formulations Reports Strong Financial Growth Amid Market Challenges

2025-11-14 11:02:29

Syncom Formulations (India) has reported impressive financial results for the quarter ending September 2025, with a 72.46% increase in Profit After Tax and a 25.87% rise in net sales. The company achieved its highest Return on Capital Employed and demonstrated strong operational efficiency, despite facing recent market challenges.

Is Syncom Formul. overvalued or undervalued?

2025-11-14 08:11:13

As of 13 November 2025, the valuation grade for Syncom Formulations has moved from expensive to very expensive. This indicates a significant shift in the perception of the company's valuation, suggesting that it is currently overvalued. The key ratios reflect this assessment, with a PE Ratio of 25.08, an EV to EBITDA of 22.41, and a Price to Book Value of 4.62, all of which are elevated compared to industry norms. In comparison to its peers, Syncom Formulations' valuation metrics stand out unfavorably. For instance, Sun Pharma has a PE Ratio of 36.15, while Divi's Lab shows an even higher valuation at 70.4. In contrast, Cipla, which is rated as attractive, has a much lower PE Ratio of 22.65, indicating that Syncom Formulations is not only overvalued but also less competitive in terms of valuation relative to its peers. Additionally, while Syncom has shown strong returns over the long term, its recent perfo...

How has been the historical performance of Syncom Formul.?

2025-11-13 00:24:52

Answer: The historical performance of Syncom Formul. shows significant fluctuations in key financial metrics over the years. Breakdown: Syncom Formul. reported net sales of 465.01 Cr for the year ending March 2025, a substantial increase from 263.39 Cr in March 2024 and 224.25 Cr in March 2023. However, this is a stark contrast to the exceptionally high net sales of 21,966.32 Cr recorded in March 2022. The company's total operating income mirrored this trend, reaching 465.01 Cr in March 2025, up from 263.39 Cr in the previous year. The total expenditure, excluding depreciation, was 410.88 Cr in March 2025, which also increased from 233.74 Cr in March 2024. Operating profit (PBDIT) for March 2025 was 71.56 Cr, showing a rise from 43.18 Cr in March 2024, while profit before tax was reported at 65.51 Cr, up from 33.95 Cr. The profit after tax for March 2025 was 49.43 Cr, compared to 25.31 Cr in March 2024. Th...

View All News